These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4235 related articles for article (PubMed ID: 23880506)

  • 1. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
    Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
    Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon nanotubes for delivery of small molecule drugs.
    Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G
    Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in drug delivery systems for targeting cancer stem cells.
    Duan H; Liu Y; Gao Z; Huang W
    Acta Pharm Sin B; 2021 Jan; 11(1):55-70. PubMed ID: 33532180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.
    Kirtane AR; Kalscheuer SM; Panyam J
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1731-47. PubMed ID: 24036273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioresponsive functional nanogels as an emerging platform for cancer therapy.
    Huang D; Qian H; Qiao H; Chen W; Feijen J; Zhong Z
    Expert Opin Drug Deliv; 2018 Jul; 15(7):703-716. PubMed ID: 29976103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.
    Zhang M; Hu W; Cai C; Wu Y; Li J; Dong S
    Mater Today Bio; 2022 Mar; 14():100223. PubMed ID: 35243298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
    Eljack S; David S; Faggad A; Chourpa I; Allard-Vannier E
    Int J Pharm X; 2022 Dec; 4():100126. PubMed ID: 36147518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in nanomedicines for malaria treatment.
    Aditya NP; Vathsala PG; Vieira V; Murthy RS; Souto EB
    Adv Colloid Interface Sci; 2013 Dec; 201-202():1-17. PubMed ID: 24192063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
    Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
    Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 212.